{"@context":"//schema.org","@graph":[{"@type":"Article","@id":"//dianhuaminglu.com/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%98%bf%e8%be%be%e6%9c%a8%e5%8d%95%e6%8a%97%e5%a2%9e%e5%8a%a0%e9%80%82%e5%ba%94%e7%97%87%e8%a1%a5%e5%85%85%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e5%8f%97%e7%90%86/#article","isPartOf":{"@id":"//dianhuaminglu.com/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%98%bf%e8%be%be%e6%9c%a8%e5%8d%95%e6%8a%97%e5%a2%9e%e5%8a%a0%e9%80%82%e5%ba%94%e7%97%87%e8%a1%a5%e5%85%85%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e5%8f%97%e7%90%86/"},"author":{"name":"Junshi","@id":"//dianhuaminglu.com/#/schema/person/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"君实生物阿达木单抗增加适应症补充申请获得受?,"datePublished":"2022-08-17T06:52:45+00:00","dateModified":"2023-01-10T07:07:26+00:00","mainEntityOfPage":{"@id":"//dianhuaminglu.com/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%98%bf%e8%be%be%e6%9c%a8%e5%8d%95%e6%8a%97%e5%a2%9e%e5%8a%a0%e9%80%82%e5%ba%94%e7%97%87%e8%a1%a5%e5%85%85%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e5%8f%97%e7%90%86/"},"wordCount":30,"commentCount":0,"publisher":{"@id":"//dianhuaminglu.com/#organization"},"image":{"@id":"//dianhuaminglu.com/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%98%bf%e8%be%be%e6%9c%a8%e5%8d%95%e6%8a%97%e5%a2%9e%e5%8a%a0%e9%80%82%e5%ba%94%e7%97%87%e8%a1%a5%e5%85%85%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e5%8f%97%e7%90%86/#primaryimage"},"thumbnailUrl":"//dianhuaminglu.com/wp-content/uploads/2022/08/迈威封面.png","inLanguage":"zh-CN","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["//dianhuaminglu.com/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%98%bf%e8%be%be%e6%9c%a8%e5%8d%95%e6%8a%97%e5%a2%9e%e5%8a%a0%e9%80%82%e5%ba%94%e7%97%87%e8%a1%a5%e5%85%85%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e5%8f%97%e7%90%86/#respond"]}]},{"@type":"WebPage","@id":"//dianhuaminglu.com/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%98%bf%e8%be%be%e6%9c%a8%e5%8d%95%e6%8a%97%e5%a2%9e%e5%8a%a0%e9%80%82%e5%ba%94%e7%97%87%e8%a1%a5%e5%85%85%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e5%8f%97%e7%90%86/","url":"//dianhuaminglu.com/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%98%bf%e8%be%be%e6%9c%a8%e5%8d%95%e6%8a%97%e5%a2%9e%e5%8a%a0%e9%80%82%e5%ba%94%e7%97%87%e8%a1%a5%e5%85%85%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e5%8f%97%e7%90%86/","name":"君实生物阿达木单抗增加适应症补充申请获得受?- 君实生物","isPartOf":{"@id":"//dianhuaminglu.com/#website"},"primaryImageOfPage":{"@id":"//dianhuaminglu.com/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%98%bf%e8%be%be%e6%9c%a8%e5%8d%95%e6%8a%97%e5%a2%9e%e5%8a%a0%e9%80%82%e5%ba%94%e7%97%87%e8%a1%a5%e5%85%85%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e5%8f%97%e7%90%86/#primaryimage"},"image":{"@id":"//dianhuaminglu.com/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%98%bf%e8%be%be%e6%9c%a8%e5%8d%95%e6%8a%97%e5%a2%9e%e5%8a%a0%e9%80%82%e5%ba%94%e7%97%87%e8%a1%a5%e5%85%85%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e5%8f%97%e7%90%86/#primaryimage"},"thumbnailUrl":"//dianhuaminglu.com/wp-content/uploads/2022/08/迈威封面.png","datePublished":"2022-08-17T06:52:45+00:00","dateModified":"2023-01-10T07:07:26+00:00","breadcrumb":{"@id":"//dianhuaminglu.com/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%98%bf%e8%be%be%e6%9c%a8%e5%8d%95%e6%8a%97%e5%a2%9e%e5%8a%a0%e9%80%82%e5%ba%94%e7%97%87%e8%a1%a5%e5%85%85%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e5%8f%97%e7%90%86/#breadcrumb"},"inLanguage":"zh-CN","potentialAction":[{"@type":"ReadAction","target":["//dianhuaminglu.com/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%98%bf%e8%be%be%e6%9c%a8%e5%8d%95%e6%8a%97%e5%a2%9e%e5%8a%a0%e9%80%82%e5%ba%94%e7%97%87%e8%a1%a5%e5%85%85%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e5%8f%97%e7%90%86/"]}]},{"@type":"ImageObject","inLanguage":"zh-CN","@id":"//dianhuaminglu.com/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%98%bf%e8%be%be%e6%9c%a8%e5%8d%95%e6%8a%97%e5%a2%9e%e5%8a%a0%e9%80%82%e5%ba%94%e7%97%87%e8%a1%a5%e5%85%85%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e5%8f%97%e7%90%86/#primaryimage","url":"//dianhuaminglu.com/wp-content/uploads/2022/08/迈威封面.png","contentUrl":"//dianhuaminglu.com/wp-content/uploads/2022/08/迈威封面.png","width":13350,"height":5688},{"@type":"BreadcrumbList","@id":"//dianhuaminglu.com/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e9%98%bf%e8%be%be%e6%9c%a8%e5%8d%95%e6%8a%97%e5%a2%9e%e5%8a%a0%e9%80%82%e5%ba%94%e7%97%87%e8%a1%a5%e5%85%85%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e5%8f%97%e7%90%86/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"新闻资讯","item":"//dianhuaminglu.com/news/"},{"@type":"ListItem","position":2,"name":"君实生物阿达木单抗增加适应症补充申请获得受?}]},{"@type":"WebSite","@id":"//dianhuaminglu.com/#website","url":"//dianhuaminglu.com/","name":"君实生物","description":"创新疗法的发现、开发和商业化的生物制药公司?,"publisher":{"@id":"//dianhuaminglu.com/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"//dianhuaminglu.com/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"zh-CN"},{"@type":"Organization","@id":"//dianhuaminglu.com/#organization","name":"君实生物","url":"//dianhuaminglu.com/","logo":{"@type":"ImageObject","inLanguage":"zh-CN","@id":"//dianhuaminglu.com/#/schema/logo/image/","url":"//dianhuaminglu.com/wp-content/uploads/2022/04/【CN-LOGO】君实生?png","contentUrl":"//dianhuaminglu.com/wp-content/uploads/2022/04/【CN-LOGO】君实生?png","width":2147,"height":795,"caption":"君实生物"},"image":{"@id":"//dianhuaminglu.com/#/schema/logo/image/"}},{"@type":"Person","@id":"//dianhuaminglu.com/#/schema/person/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"//dianhuaminglu.com/author/junshi/"}]}
北京时间2022??6日,君实生物?877.HK?88180.SH)宣布,国家药品监督管理局(NMPA)已受理公司与迈威生物(688062.SH)合作开发的阿达木单抗注射液(商品名:君迈康®,君实生物项目代码:UBP1211,迈威生物项目代码:9MW0113)的增加适应症补充申请,用于治疗克罗恩病(CD)、葡萄膜炎(UV)、多关节型幼年特发性关节炎(PJIA)、儿童斑块状银屑病(Ped Ps)、儿童克罗恩病(Ped CD)?/p>
肿瘤坏死因子(TNF-α)由巨噬细胞、肥大细胞和被激活的TH细胞分泌,为炎症反应的强效诱导剂和先天免疫的关键调节器,在多种炎症的发生和发展中处于核心地位。TNF-α和TNF-α受体结合可诱导炎症反应,现已证明,类风湿关节炎、银屑病、克罗恩病、强直性脊柱炎等多种自身免疫性疾病与TNF-α密切相关。抗TNF-α单克隆抗体可结合TNF-α受体,降低TNF-α激活的免疫应答,从而阻止炎症的发生?君迈?sup>®曾获得“十二五”国家“重大新药创制”科技重大专项支持。此前,君迈?sup>®已获得NMPA批准的适应症包括类风湿关节炎、强直性脊柱炎及银屑病?/p>
关于葡萄膜炎
非感染性中间、后、全葡萄膜炎是一组免疫介导的眼内炎症性疾病,可能引起患者虹膜粘连、青光眼、白内障、黄斑水肿、视网膜病变等并发症,导致视力受损甚至失明,通常与免疫介导引发的系统性疾病如银屑病、强直性脊柱炎等共同发生。中国大陆流行病学的研究数据显示其发病率?52/100,000,发病率高峰?4-44岁?/p>
关于克罗恩病
一种慢性、易反复的炎症性胃肠道疾病,与溃疡性结肠炎(Ulcerative Colitis, UC)同属于炎症性肠病(Inflammatory bowel disease, IBD)。在中国,克罗恩病的患病率为2.29/100,000,平均发病率1.21/100,000,且呈不断快速上升的趋势。克罗恩病目前尚无法完全治愈,治疗目标在于诱导并维持缓解,防治并发症,改善生活质量?/p>
关于儿童克罗恩病
据统计,世界上所有炎症性肠病患者中?5%?0%是儿童,其中克罗恩病占绝大部分,且其发病率呈逐年增高趋势?/p>
关于多关节型幼年特发性关节炎
幼年特发性关节炎是儿童时期常见的风湿性疾病,以慢性关节滑膜炎为主要特征,并伴有全身多脏器功能损害,亦是造成儿童时期残疾和失明的重要病因。多关节型幼年特发性关节炎是幼年特发性关节炎较为常见的亚型,约占18%~30%?/p>
关于儿童斑块状银屑病
儿童银屑病是一种发生于儿童、由免疫介导的慢性、复发性、炎症性、系统性疾病,不同人群、种族、性别普遍易感,大?/3的患者在儿童期发病。年龄较大的儿童银屑病常见类型为斑块状银屑病?5%),其次为点滴状银屑病(15%~30%)、泛发性脓疱型银屑病(1%~5.4%)?/p>